DOCSLIB.ORG

Non-FDA Approved Medication and Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non-FDA Approved Medication and Product List Non-FDA approved medication and product list. *Note: Non-FDA approved medications/products are listed by NDC. This list is subject to change. Updated 7/27/21 NDC PRODUCT NAME 69094022702 1ST BASE CRE 72137011315 1ST MEDX-PTC PAD LIDOCAIN 49452245201 2-DEOXY-D POW -GLUCOSE 49452245202 2-DEOXY-D POW -GLUCOSE 49452245203 2-DEOXY-D POW -GLUCOSE 51552057901 2-DEOXY-D POW -GLUCOSE 51552057902 2-DEOXY-D POW -GLUCOSE 51927177300 2-DEOXY-D POW -GLUCOSE 70175021101 2-DEOXY-D POW -GLUCOSE 71092998101 2-DEOXY-D POW -GLUCOSE 71092998102 2-DEOXY-D POW -GLUCOSE 46144014210 2-METHOXYEST POW 51927446100 2-METHOXYEST POW 46144020105 4 AMINOPYRID POW 46144020110 4 AMINOPYRID POW 51552093904 4 AMINOPYRID POW 51927242300 4 AMINOPYRID POW 51927503000 4 AMINOPYRID POW 71052064501 4 AMINOPYRID POW 75839064501 4 AMINOPYRID POW 51927232500 4-AMINOBUTYR CRY ACID 38779000124 5-AMINOSALIC POW ACID 38779000125 5-AMINOSALIC POW ACID 38779000128 5-AMINOSALIC POW ACID 38779000129 5-AMINOSALIC POW ACID 49452045001 5-AMINOSALIC POW ACID 49452045003 5-AMINOSALIC POW ACID 49452045004 5-AMINOSALIC POW ACID 51552132604 5-AMINOSALIC POW ACID 51552132605 5-AMINOSALIC POW ACID 51552132606 5-AMINOSALIC POW ACID 51927107800 5-AMINOSALIC POW ACID 62991133302 5-HYDROXY-L- POW TRYPTOPH 62991133303 5-HYDROXY-L- POW TRYPTOPH 62991133304 5-HYDROXY-L- POW TRYPTOPH 62991133305 5-HYDROXY-L- POW TRYPTOPH 54288122201 5-METHYLTETR POW 54288122202 5-METHYLTETR POW NDC PRODUCT NAME 10695009914 5-METHYLTETR POW CALCIUM 62991310801 5-METHYLTETR POW CALCIUM 62991310802 5-METHYLTETR POW CALCIUM 62991310803 5-METHYLTETR POW CALCIUM 70175020901 5-METHYLTETR POW CALCIUM 70457996801 5-METHYLTETR POW CALCIUM 70457996802 5-METHYLTETR POW CALCIUM 70457996803 5-METHYLTETR POW CALCIUM 51552076305 6-AMINOCAPRO POW ACID 51552076307 6-AMINOCAPRO POW ACID 00395810719 7-KETO DHEA POW 00395810762 7-KETO DHEA POW 38779241803 7-KETO DHEA POW 38779241804 7-KETO DHEA POW 38779241805 7-KETO DHEA POW 38779241808 7-KETO DHEA POW 38779241809 7-KETO DHEA POW 49452244901 7-KETO DHEA POW 49452244902 7-KETO DHEA POW 49452244903 7-KETO DHEA POW 49452244904 7-KETO DHEA POW 51552101703 7-KETO DHEA POW 51552101705 7-KETO DHEA POW 51927334100 7-KETO DHEA POW 62991250501 7-KETO DHEA POW 62991250502 7-KETO DHEA POW 62991250503 7-KETO DHEA POW 62991250504 7-KETO DHEA POW 63275992404 7-KETO DHEA POW 63275992405 7-KETO DHEA POW 63275992408 7-KETO DHEA POW 63275992409 7-KETO DHEA POW 70645050088 7T GUMMY ES CHW 500MG 51927153800 9-AMINOACRID POW HCL 50488200301 A.A.G.C KIT CRE TERODERM 50488200302 A.A.G.C KIT CRE TERODERM 52083061210 ABANEU-SL SUB 51927443100 AC DERMAPEPT LIQ 38779006001 ACACIA POW 38779006005 ACACIA POW 38779006008 ACACIA POW 49452000501 ACARBOSE POW 49452000502 ACARBOSE POW 49452000503 ACARBOSE POW 49452000504 ACARBOSE POW 76420071501 ACCUCAINE INJ 1% NDC PRODUCT NAME 51927290600 ACEBUTOLOL POW 38779017204 ACEPROMAZINE POW MALEATE 38779017205 ACEPROMAZINE POW MALEATE 38779017208 ACEPROMAZINE POW MALEATE 38779017209 ACEPROMAZINE POW MALEATE 51927357400 ACEPROMAZINE POW MALEATE 62991298101 ACEPROMAZINE POW MALEATE 62991298102 ACEPROMAZINE POW MALEATE 62991298103 ACEPROMAZINE POW MALEATE 62991298104 ACEPROMAZINE POW MALEATE 38779259004 ACESULFAME POW POTASSIU 38779259005 ACESULFAME POW POTASSIU 38779259008 ACESULFAME POW POTASSIU 38779259009 ACESULFAME POW POTASSIU 38779317104 ACESULFAME POW POTASSIU 38779317105 ACESULFAME POW POTASSIU 38779317108 ACESULFAME POW POTASSIU 38779317109 ACESULFAME POW POTASSIU 49452344901 ACESULFAME POW POTASSIU 49452344902 ACESULFAME POW POTASSIU 49452344903 ACESULFAME POW POTASSIU 49452344904 ACESULFAME POW POTASSIU 51927439800 ACESULFAME POW POTASSIU 62991256801 ACESULFAME POW POTASSIU 62991256802 ACESULFAME POW POTASSIU 62991256803 ACESULFAME POW POTASSIU 62991256804 ACESULFAME POW POTASSIU 63307001011 ACESULFAME POW POTASSIU 63307001015 ACESULFAME POW POTASSIU 49452000901 ACETAMIN GRA 49452000902 ACETAMIN GRA 49452000905 ACETAMIN GRA 38779040901 ACETAMIN POW 38779040905 ACETAMIN POW 38779040907 ACETAMIN POW 38779040908 ACETAMIN POW 38779040909 ACETAMIN POW 60592000101 ACETAMIN POW 60592000105 ACETAMIN POW 60592000110 ACETAMIN POW 60592000111 ACETAMIN POW 60592000145 ACETAMIN POW 62991100202 ACETAMIN POW USP/NF 62991100203 ACETAMIN POW USP/NF 62991100206 ACETAMIN POW USP/NF 70092143546 ACETAMINOPHE SOL 100MG NDC PRODUCT NAME 51927429300 ACETARSONE POW 38779004104 ACETAZOLAMID POW 38779004105 ACETAZOLAMID POW 38779041004 ACETAZOLAMID POW 38779041005 ACETAZOLAMID POW 38779041007 ACETAZOLAMID POW 38779041009 ACETAZOLAMID POW 49452001802 ACETAZOLAMID POW 49452001803 ACETAZOLAMID POW 49452001804 ACETAZOLAMID POW 51927227600 ACETAZOLAMID POW 62991251701 ACETAZOLAMID POW 62991251702 ACETAZOLAMID POW 62991251703 ACETAZOLAMID POW 62991251704 ACETAZOLAMID POW 62991251705 ACETAZOLAMID POW 51552005506 ACETIC ACID SOL 5% 51552005508 ACETIC ACID SOL 5% 38779005828 ACETIC ACID SOL GLACIAL 38779058201 ACETIC ACID SOL GLACIAL 38779058208 ACETIC ACID SOL GLACIAL 51927129700 ACETIC ACID SOL GLACIAL 62991274501 ACETIC ACID SOL GLACIAL 62991274502 ACETIC ACID SOL GLACIAL 51927188800 ACETONE SOL 62991283901 ACETONE SOL 62991283902 ACETONE SOL 62991283903 ACETONE SOL 51927377100 ACETYL DIPEP SOL CETYL ES 51927232600 ACETYLCHOLIN POW CHLORIDE 00395822356 ACETYLCYST POW 00395822362 ACETYLCYST POW 38779049504 ACETYLCYST POW 38779049505 ACETYLCYST POW 38779049507 ACETYLCYST POW 38779049508 ACETYLCYST POW 38779049509 ACETYLCYST POW 38779270004 ACETYLCYST POW 38779270005 ACETYLCYST POW 38779270008 ACETYLCYST POW 38779270009 ACETYLCYST POW 49452009701 ACETYLCYST POW 49452009702 ACETYLCYST POW 49452009703 ACETYLCYST POW 49452009704 ACETYLCYST POW 51552020104 ACETYLCYST POW NDC PRODUCT NAME 51552020105 ACETYLCYST POW 51552020107 ACETYLCYST POW 51927160100 ACETYLCYST POW 62991100301 ACETYLCYST POW 62991100302 ACETYLCYST POW 62991100303 ACETYLCYST POW 62991100304 ACETYLCYST POW 62991100307 ACETYLCYST POW 00517750401 ACETYLCYST SOL 10% 00517760401 ACETYLCYST SOL 20% 38779095804 ACETYL-L-CAR POW HCL 38779095805 ACETYL-L-CAR POW HCL 38779095809 ACETYL-L-CAR POW HCL 51927261100 ACETYL-L-CAR POW HCL 62991163701 ACETYL-L-CAR POW HCL 62991163702 ACETYL-L-CAR POW HCL 62991163703 ACETYL-L-CAR POW HCL 38779095501 ACETYLSALICY POW ACID USP 38779095505 ACETYLSALICY POW ACID USP 38779095507 ACETYLSALICY POW ACID USP 38779095508 ACETYLSALICY POW ACID USP 38779095509 ACETYLSALICY POW ACID USP 51927352200 ACIDO LACTOB POW 10BU/GM 62991313701 ACIDO LACTOB POW 10BU/GM 62991313702 ACIDO LACTOB POW 10BU/GM 62991313703 ACIDO LACTOB POW 10BU/GM 62991313704 ACIDO LACTOB POW 10BU/GM 51927424400 ACIDO LACTOB POW 1BU/GM 62991200101 ACIDO LACTOB POW 1BU/GM 62991200102 ACIDO LACTOB POW 1BU/GM 62991200103 ACIDO LACTOB POW 1BU/GM 62991200104 ACIDO LACTOB POW 1BU/GM 38779242703 ACIDOPHILUS POW LACTOBAC 38779242705 ACIDOPHILUS POW LACTOBAC 38779242708 ACIDOPHILUS POW LACTOBAC 38779242709 ACIDOPHILUS POW LACTOBAC 72934241402 ACIOXIAY CRE 15-4% 63347092001 ACNESIC GEL 0.5% 38779009624 ACRIFLAVINE POW NEUTRAL 40565012498 ACTCT FLEX 3 PAD 4"X4" 51927509400 ACTIPHYTE LIQ SEA KELP 51927510300 ACTIPHYTE LIQ SUG KELP 51927411800 ACTIPHYTE OF LIQ ALGAE 51927411700 ACTIPHYTE OF LIQ CUCUMBER 51927411900 ACTIPHYTE OF LIQ IVY 51927411400 ACTIPHYTE OF LIQ LEMONGRA NDC PRODUCT NAME 45861012401 ACTIVE KIT INJECT L 28595043330 ACTIVE FE TAB 75-1.25 45861013201 ACTIVE INJEC INJ DL 45861013401 ACTIVE INJEC INJ M-1 45861012901 ACTIVE INJEC KIT BLM-1 45861012801 ACTIVE INJEC KIT BM 45861013301 ACTIVE INJEC KIT D 45861013101 ACTIVE INJEC KIT DLM 45861013601 ACTIVE INJEC KIT KET-L 45861013501 ACTIVE INJEC KIT KETMARC 45861012501 ACTIVE INJEC KIT KL-3 45861011701 ACTIVE INJEC KIT KM 45861013701 ACTIVE INJEC KIT LM-2 45861013901 ACTIVE INJEC KIT LM-DEP-1 45861014101 ACTIVE INJEC KIT LM-DEP-2 45861010801 ACTIVE-PAC/ MIS GABA 300 45861011201 ACTIVE-PREP CRE KIT I 45861011202 ACTIVE-PREP CRE KIT I 45861011203 ACTIVE-PREP CRE KIT I 45861011301 ACTIVE-PREP CRE KIT II 45861011302 ACTIVE-PREP CRE KIT II 45861011303 ACTIVE-PREP CRE KIT II 45861011401 ACTIVE-PREP CRE KIT III 45861011402 ACTIVE-PREP CRE KIT III 45861011501 ACTIVE-PREP CRE KIT IV 45861011502 ACTIVE-PREP CRE KIT IV 45861011503 ACTIVE-PREP CRE KIT IV 45861011601 ACTIVE-PREP CRE KIT V 45861011602 ACTIVE-PREP CRE KIT V 45861011603 ACTIVE-PREP CRE KIT V 69967000601 ACTIVITE TAB 68489000027 ACUICYN LIQ 68489000028 ACUICYN LIQ 89116000018 ACUICYN LIQ 89116000022 ACUICYN LIQ 61480013705 ACUNOL TAB 600MG 00395809719 ACYCLOVIR POW 00395809762 ACYCLOVIR POW 38779001731 ACYCLOVIR POW 38779001734 ACYCLOVIR POW 38779001735 ACYCLOVIR POW 38779017301 ACYCLOVIR POW 38779017304 ACYCLOVIR POW 38779017305 ACYCLOVIR POW 38779017308 ACYCLOVIR POW 49452000101 ACYCLOVIR POW NDC PRODUCT NAME 49452000102 ACYCLOVIR POW 49452000103 ACYCLOVIR POW 49452000104 ACYCLOVIR POW 49452000105 ACYCLOVIR POW 49452000106 ACYCLOVIR POW 49452000108 ACYCLOVIR POW 51552067101 ACYCLOVIR POW 51552067102 ACYCLOVIR POW 51552067103 ACYCLOVIR POW 51552067104 ACYCLOVIR POW 51552067105 ACYCLOVIR POW 51552067106 ACYCLOVIR POW 51927299400 ACYCLOVIR POW 60592000601 ACYCLOVIR POW 60592000605 ACYCLOVIR POW 60592000611 ACYCLOVIR POW 60592000625 ACYCLOVIR POW 62991100401 ACYCLOVIR POW 62991100402 ACYCLOVIR POW 62991100403 ACYCLOVIR POW 62991100404 ACYCLOVIR POW 62991100405 ACYCLOVIR POW 63307001611 ACYCLOVIR POW 63307001615 ACYCLOVIR POW 63307001639 ACYCLOVIR POW 70457989303 ACYCLOVIR POW 70457989304 ACYCLOVIR POW 71092998001 ACYCLOVIR POW 71092998002 ACYCLOVIR POW 71092998003 ACYCLOVIR POW 71092998004 ACYCLOVIR POW 71092998005 ACYCLOVIR POW 71092998006 ACYCLOVIR
Load more

Recommended publications
  • Vasodilators for Primary Raynaud's Phenomenon
    Vasodilators for primary Raynaud's phenomenon Author Su, KYC, Sharma, M, Kim, HJ, Kaganov, E, Hughes, I, Abdeen, MH, Ng, JHK Published 2021 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD006687.pub4 Copyright Statement © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687.. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/405317 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Vasodilators for primary Raynaud's phenomenon (Review) Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JHK Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JH. Vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687. DOI: 10.1002/14651858.CD006687.pub4. www.cochranelibrary.com Vasodilators for primary Raynaud's phenomenon (Review) Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER........................................................................................................................................................................................................
    [Show full text]
  • DHEA: Dehydroepiandrosterone
    DHEA: Dehydroepiandrosterone Joseph Pepping, Pharm.D. [Am J Health-Syst Pharm 57(22):2048-2056, 2000. © 2000 ASHP, Inc.] Introduction Dehydroepiandrosterone (DHEA) and its active metabolite, DHEA sulfate (DHEAS), are endogenous hormones synthesized and excreted primarily by the zona reticularis of the adrenal cortex in response to adrenocorticotropic hormone. The exact mechanism of action and clinical role, if any, of DHEA and DHEAS remain unclear. Epidemiological data indicate an inverse relationship between serum DHEA and DHEAS levels and the frequency of cancer, cardiovascular disease (in men only), Alzheimer's disease and other age-related disorders, immune function, and progression of HIV infection. [1] Animal (primarily rodent) studies have suggested many beneficial effects of DHEA, including improved immune function and memory and prevention of atherosclerosis, cancer, diabetes, and obesity. Many of the benefits seen in animal studies have yet to be shown in humans. [1-3] Uses Clinically substantiated (yet still controversial) uses of DHEA include replacement therapy in patients with low serum DHEA levels secondary to chronic disease, adrenal exhaustion, or corticosteroid therapy; treating systemic lupus erythematosus (SLE), improving bone density in postmenopausal women; improving symptoms of severe depression; improving depressed mood and fatigue in patients with HIV infection; and increasing the rate of reepithelialization in patients undergoing autologous skin grafting for burns. [1,4-8] Other possible uses (with some supporting clinical studies) include enhancing the immune response and sense of well-being in the elderly, decreasing certain cardiovascular risk factors, and treating male erectile dysfunction. [4,8-12] Use of DHEA to slow or reverse the aging process, improve cognitive function, promote weight loss, increase lean muscle mass, or slow the progression of Parkinson's disease and Alzheimer's disease is clinically unsubstantiated.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Exerts Anxiolytic-Like Effects Through GABAA Receptors in a Surgical Menopause Model in Rats
    Biomedicine & Pharmacotherapy 109 (2019) 2387–2395 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Original article Chrysin (5,7-dihydroxyflavone) exerts anxiolytic-like effects through GABAA receptors in a surgical menopause model in rats T ⁎ Juan Francisco Rodríguez-Landaa,b, , Fabiola Hernández-Lópezc, Jonathan Cueto-Escobedoa, Emma Virginia Herrera-Huertad, Eduardo Rivadeneyra-Domínguezb, Blandina Bernal-Moralesa,b, Elizabeth Romero-Avendañod a Laboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Veracruz, Mexico b Facultad de Química Farmacéutica Biológica, Universidad Veracruzana, Xalapa, Veracruz, Mexico c Hospital General de Zona con Medicina Familiar No. 28, Delegación Veracruz Norte, Instituto Mexicano del Seguro Social (H.G.Z. c/mf. No. 28, Delegación Veracruz Norte, IMSS), Martínez de la Torre, Veracruz, Mexico d Facultad de Ciencias Químicas, Universidad Veracruzana, Orizaba, Veracruz, Mexico ARTICLE INFO ABSTRACT Keywords: The present study investigated the effects of the flavonoid chrysin (5,7-dihydroxyflavone) on anxiety-like be- Anxiolytics havior in rats in a model of surgical menopause and evaluated the participation of γ-aminobutyric acid-A Chrysin (GABAA) receptors in these actions. At 12 weeks post-ovariectomy, the effects of different doses of chrysin (0.5, GABAA 1, 2, and 4 mg/kg) were evaluated in the elevated plus maze, light/dark test, and locomotor activity test, and Oophorectomy comparisons were made with the clinically effective anxiolytic diazepam. The participation of GABA receptors Ovariectomy A in the actions of chrysin was explored by pretreating the rats with the noncompetitive GABA chloride ion Surgical menopause A channel antagonist picrotoxin (1 mg/kg). The results showed that chrysin (2 and 4 mg/kg) reduced anxiety-like behavior in both the elevated plus maze and light/dark test, and these effects were similar to diazepam.
    [Show full text]
  • This Table Summarizes Changes to the HF Qxq As of 10/11/2019 Question
    Updated HFS Instructions (QxQs) This table summarizes changes to the HF QxQ as of 10/11/2019 Question in HF QxQ Description of Changes in HF QXQ General Instructions, pg. 3 Clarification added to rules for history Q29.d.10., pg. 40 Clarification made on how to record pulmonary hypertention Q29.d.14., pg. 41 Clarification made on how to record diastolic dysfunction Q42., pg. 42 Clarification made on how to record troponin I Section VII: Medication, pg. 54 Clarificaiton made on how to record medications Appendix A, pg. 61 Updated list of medications Edoxaban (ACOAG, Generic) Lixiana (ACOAG, Trade) Prexxartan (ARB, Trade) INSTRUCTIONS FOR COMPLETING HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM HFS Version C, 10/1/2015 HFA Version D, 10/1/2015 HF QxQ, 10/11/2019 Table of Contents Page General Instructions……………………………………………………………….. 2 Specific Items………………………………………………………………………. 3 Section l: Screening for Decompensation………………………………….. 5 Section ll: History of Heart Failure…………………………………………... 10 Section lll: Medical History ………………………………………………….. 13 Section lV: Physical Exam - Vital Signs…………………………………….. 24 Section V: Physical Exam - Findings……………………………………….. 26 Section Vl: Diagnostic Tests…………………………………………………. 31 Section Vll: Biochemical Analyses………………………………………….. 48 Section Vlll: Interventions…………………………………………………….. 51 Section lX: Medications………………………………………………………. 54 Section X: Complications Following Events………………………………… 59 Section Xl: Administrative……………………………………………………. 60 Appendix A: ARIC Heart Failure/Cardiac Drugs: ………………………………. 61 Alphabetical Sort Appendix B: Potential Scenarios of the Onset of Heart………………………. 73 Failure Event or Decompensation HF QxQ 10/11/2019 Page 1 of 73 General Instructions The HFAA form was initially used for all discharges selected for HF surveillance. It was replaced by the HFAB and HFSA forms and then updated June 2012 with HFAC and HFSB.
    [Show full text]
  • Updatirg the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
    Updatirg the BeersCriteria for Potentially InappropriateMedication Use in Older Adults Resultsof a US ConsensusPanel of Experts DonnaM.Fich,PhD,RN;lamesW.Cooper,PhD,RPh;WilliamE.Wade,PhannD,FASHP,FCCP; JenniJerL. Waller, PhD;J, RossMaclean, MD; Marh H. Beers,MD Bcckground: Medication toxic effectsand drug- Reruhr: This study identified 48 individual medica- relatedproblems can have profound medical and safety tions or classeso[ medicationsto avoid in older adults consequencesfor older adults and economically affect the and their potential concernsand 20 diseases/conditions health caresystem. The purpose of this initiative was to and medicationsto be avoidedin older adultswith these reviseand update the Beerscriteria for potentially inap- conditions.Of thesepotentially inappropriate drugs, 66 propriate medicationuse in adults 65 yearsand older in wereconsidered by the panelto haveadverse outcomes the United States. of high severity. lYlcthcdr: This study used a modified Delphi method, a Concludonr: This study is an importantupdate of pre- setof proceduresand methodsfor formulating a groupjudg- viously establishedcriteria that have been widely used ment for a subject matter in which precise information is and cited. The application of the Beerscriteria and other Iacking. The criteria reviewed covered 2 types of state- tools for identifying potentially inapproprlate medica- ments: (l) medicationsor medicationclasses that should tion use will continue to enableproviders to plan inter- grnerally be avoidedin persons 65 years or older because
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]